Review Article in Poorly Differentiated Cancer Thyroid, An overview. | ||||
| Minia Journal of Medical Research | ||||
| Volume 31, Issue 4, October 2020, Page 141-143 PDF (99.71 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2022.217551 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Mai S. Khalifa1; Asmaa H. Fathy2 | ||||
| 1Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine and Sohag University | ||||
| 2Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine and Sohag University | ||||
| Abstract | ||||
| Worldwide, the incidence of thyroid cancer has greatly increased in the last decades with female predominance. Increase in incidence of more advanced disease has also been reported. Poorly differentiated thyroid cancer is a rare aggressive subtype of thyroid cancer that does not appear de-novo from the start, it starts as differentiated cancer then dedifferentiation occurs by genetic factors. It is the main cause of death from non-anaplastic follicular cell derived thyroid cancer. It expresses thyroglobulin, as differentiated thyroid cancers and usually does not concentrate radioactive iodine with increased glucose transporter 1 expression, like anaplastic thyroid cancers. This type of cancer has high risk of local recurrence and distant metastasis. Management of this type of cancer is challenging with overall poor therapy response and prognosis with high mortality rate when compared to differentiated thyroid cancers. Surgery is the standard management in early operable cases followed by radioactive iodine therapy (after testing avidity)/radiotherapy/chemotherapy and the recently available molecular targeted therapies are promising. | ||||
| Keywords | ||||
| Poorly differentiated thyroid cancer; incidence; prognosis; management; chemotherapy; radioactive iodine; PET/CT | ||||
|
Statistics Article View: 62 PDF Download: 121 |
||||
